Intra-Cellular Therapies Inc (NASDAQ:ITCI)
| 51.40 Delayed Data As of Aug 19 |  +0.66 / +1.30%Today’s Change | 28.45 Today|||52-Week Range 66.00 | -1.80% Year-to-Date |
Latest ITCI News | Press Releases
| Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates Aug 09 / Zacks.com - Paid Partner Content | Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season? Aug 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 50.74 |
| Today’s open | 50.17 |
| Day’s range | 50.17 - 52.04 |
| Volume | 30,666 |
| Average volume (3 months) | 814,703 |
| Market cap | $5.1B |
Data as of 4:00pm ET, 08/19/2022
Growth & Valuation
| Earnings growth (last year) | -8.39% |
| Earnings growth (this year) | +8.49% |
| Earnings growth (next 5 years) | +2.50% |
| Revenue growth (last year) | +267.35% |
| P/E ratio | NM |
| Price/Sales | 50.75 |
| Price/Book | 10.50 |
Competitors
Data as of 3:59pm ET, 08/19/2022
Financials
| Next reporting date | November 9, 2022 |
| EPS forecast (this quarter) | -$0.80 |
| Annual revenue (last year) | $83.8M |
| Annual profit (last year) | -$284.1M |
| Net profit margin | -339.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
